New malaria pill shows promise in early trial
NCT ID NCT07235020
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested an experimental drug called INE963 in 52 adults with uncomplicated Plasmodium falciparum malaria. The main goal was to see how quickly the drug clears malaria parasites from the blood. Researchers also checked the 28-day cure rate. The study is part of a larger platform trial and has already been completed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- INE963 (an experimental antimalarial drug taken by mouth)
- What this could lead to
- If successful, this could point toward a new oral treatment for uncomplicated malaria, potentially offering an alternative to existing drugs.
- What could go wrong
- This is a small, early-phase trial (Phase 2) with only 52 participants, so results may not apply broadly. The drug may not work as well in larger studies or in different populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Banfora, Burkina Faso
-
Novartis Investigative Site
Azaguié, BP 173, Côte d’Ivoire
-
Novartis Investigative Site
Lambaréné, BP 242, Gabon
-
Novartis Investigative Site
Navrongo, VWJ6+8WF, Ghana
-
Novartis Investigative Site
Kisumu, 40100, Kenya
-
Novartis Investigative Site
Kampala, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.